TOPIRAMATE
Total Payments
$364,028
Transactions
121
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1,320 | 1 | 0 |
| 2023 | $106,121 | 40 | 2 |
| 2022 | $99,741 | 42 | 2 |
| 2021 | $156,847 | 38 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $364,028 | 121 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE | UPSHER-SMITH LABORATORIES LLC | $359,353 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE | Upsher-Smith Laboratories LLC | $4,675 | 2 |
Ad
Manufacturing Companies
- UPSHER-SMITH LABORATORIES LLC $359,353
- Upsher-Smith Laboratories LLC $4,675
Product Information
- Type Drug
- Total Payments $364,028
- Total Doctors 2
- Transactions 121
About TOPIRAMATE
TOPIRAMATE is a drug associated with $364,028 in payments to 2 healthcare providers, recorded across 121 transactions in the CMS Open Payments database. The primary manufacturer is UPSHER-SMITH LABORATORIES LLC.
Payment data is available from 2021 to 2024. In 2024, $1,320 was paid across 1 transactions to 0 doctors.
The most common payment nature for TOPIRAMATE is "Unspecified" ($364,028, 100.0% of total).
TOPIRAMATE is associated with 2 research studies, including "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QUDEXY(R) XR IN THE PREVENTION OF MIGRAINE IN CHILDREN 6 TO 11 YEARS OF AGE" ($359,353).